IL1B and Alzheimer disease: Wang et al. reported improvement in cognitive dysfunction related to spatial memory due to a protective effect that resulted in a reduction in lipid peroxidation and a decrease in the release of inflammatory mediators (IL-1 and IL-6) through the oral administration of α-Toc (100 mg/kg for four weeks) in transgenic APPswe/PS1dE9 mice previously induced to develop AD [39].